Intuitive Surgical stock (US46120E6023): robot-assisted surgery leader in focus after latest quarterly figures

Intuitive Surgical has reported fresh quarterly results and updated procedure trends for its da Vinci surgery platform, drawing renewed attention from investors to growth, profitability and hospital spending on robotics.

Intuitive Surgical has recently published new quarterly results that shed light on procedure growth, installed da Vinci surgical systems and margins, keeping the stock in focus for investors watching the medical technology and robotics space, according to the company’s earnings release on 04/18/2024 and subsequent updates on its investor relations site Intuitive Surgical IR as of 04/18/2024 and a summary from Reuters as of 04/18/2024.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Intuitive Surgical
• Sector/industry: Medical technology, robotic surgery
• Headquarters/country: Sunnyvale, United States
• Core markets: Hospitals and surgery centers in the US, Europe and Asia
• Key revenue drivers: da Vinci surgical systems, instruments and accessories, services
• Home exchange/listing venue: Nasdaq (ticker: ISRG)
• Trading currency: USD

Intuitive Surgical: core business model

Intuitive Surgical develops and markets robotic-assisted surgical platforms, with its flagship da Vinci system used in minimally invasive procedures across specialties such as urology, gynecology and general surgery, as described in its company profile and filings on the investor relations site Intuitive Surgical IR as of 02/02/2024.

The business model combines upfront capital sales of da Vinci systems with recurring revenue streams from instruments and accessories, service contracts and training, which together tend to generate a higher share of total revenue than the hardware systems themselves, according to the company’s Form 10-K for the year ended 12/31/2023 that was published on 02/02/2024 Intuitive Surgical IR as of 02/02/2024.

The company works closely with surgeons and hospitals to embed da Vinci systems in clinical workflows, offering extensive training programs and support services; this ecosystem approach is highlighted as a differentiating factor in the 2023 annual report released on 02/02/2024, which notes that procedure adoption and surgeon proficiency are key drivers of recurring revenue and long-term system utilization Intuitive Surgical IR as of 02/02/2024.

Unlike some medical device manufacturers that depend heavily on disposable products, Intuitive’s mix of installed robotics, instruments and service contracts creates a multi-year revenue stream tied to procedure volumes, which can help smooth out fluctuations in capital spending cycles but also makes the company sensitive to healthcare utilization trends and hospital budgets, as outlined in the risk factors section of its 2023 Form 10-K filed on 02/02/2024 Intuitive Surgical IR as of 02/02/2024.

Main revenue and product drivers for Intuitive Surgical

According to the company’s first-quarter 2024 earnings release for the period ended 03/31/2024, published on 04/18/2024, total revenue was 1.89 billion USD, up 11% year over year, with instruments and accessories accounting for the largest share, while system revenue and services contributed the remainder Intuitive Surgical IR as of 04/18/2024.

In the same release for Q1 2024, management reported that da Vinci procedures grew approximately 16% compared with the prior-year quarter, driven by broad-based strength in general surgery and gynecologic procedures and by continued expansion in international markets, according to Intuitive Surgical IR as of 04/18/2024.

Installed base expansion remains another key driver: the number of da Vinci systems in the field reached about 8,887 at the end of Q1 2024, up 14% year over year, with a growing portion placed under operating leases or usage-based arrangements instead of outright purchase, a trend the company highlighted in its Q1 2024 earnings commentary on 04/18/2024 Intuitive Surgical IR as of 04/18/2024.

Margin performance is influenced both by product mix and by investments in R&D and global expansion; the Q1 2024 release stated that GAAP net income was 544 million USD and that the company continued to invest in new product platforms and digital tools aimed at enhancing surgical planning and data insights, while managing costs in manufacturing and service operations, according to Intuitive Surgical IR as of 04/18/2024.

For full-year 2023, which ended on 12/31/2023 and was reported on 01/23/2024, the company generated revenue of 7.12 billion USD, an increase of 14% compared with 2022, driven primarily by a 22% rise in da Vinci procedures and growth in instruments and accessories revenue, as reported in the company’s earnings release and 2023 annual report, both referenced on the investor relations site as of 01/23/2024 and 02/02/2024 Intuitive Surgical IR as of 01/23/2024.

The 2023 Form 10-K filed on 02/02/2024 also notes that instruments and accessories represented about 56% of total revenue for 2023, systems accounted for roughly 22% and services made up the balance, illustrating the importance of recurring demand from ongoing procedures for the company’s overall revenue mix Intuitive Surgical IR as of 02/02/2024.

Another factor for revenue is geographic diversification: the 2023 annual report indicates that the United States remained the largest market but that international revenue continued to grow faster than domestic revenue, with significant contributions from Western Europe and parts of Asia, including Japan and China, according to the document released on 02/02/2024 for the fiscal year ended 12/31/2023 Intuitive Surgical IR as of 02/02/2024.

Beyond da Vinci, the company is developing complementary technologies such as the Ion endoluminal system for minimally invasive lung biopsy; in its 2023 Form 10-K filed on 02/02/2024 for the year ended 12/31/2023, Intuitive noted that Ion placements increased and that it continued to invest in clinical evidence for this platform’s role in lung cancer diagnosis Intuitive Surgical IR as of 02/02/2024.

Conclusion

Intuitive Surgical remains a central player in robot-assisted minimally invasive surgery, with recent quarterly results highlighting continued growth in da Vinci procedures, a larger installed base and expanding recurring revenue streams, according to company filings for 2023 and Q1 2024 released on 01/23/2024, 02/02/2024 and 04/18/2024 Intuitive Surgical IR as of 04/18/2024. At the same time, the business is exposed to hospital capital budgets, procedure trends and competitive dynamics in surgical robotics, all of which can influence revenue and profitability for US and international investors following the Nasdaq-listed stock.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.